Navigation Links
Cardium Reports on New Excellarate(TM) Product Formulations to Expand Commercialization Potential Into Multiple Wound Healing Applications
Date:5/7/2009

o risks and uncertainties that exist in our operations and business environment, including, without limitation, risks and uncertainties that are inherent in the development of complex biologics and therapeutic hypothermia devices and in the conduct of human clinical trials, including the timing, costs and outcomes of such trials, our ability to obtain necessary funding, regulatory approvals and expected qualifications, our ability to successfully accelerate the commercialization of our therapeutic hypothermia devices and launch new devices within the timeframes contemplated, our dependence upon proprietary technology, our history of operating losses and accumulated deficits, our reliance on collaborative relationships and critical personnel, and current and future competition, as well as other risks described from time to time in filings we make with the Securities and Exchange Commission. We undertake no obligation to release publicly the results of any revisions to these forward-looking statements to reflect events or circumstances arising after the date hereof.

Copyright 2009 Cardium Therapeutics, Inc. All rights reserved.

For Terms of Use Privacy Policy, please visit www.cardiumthx.com.

Cardium Therapeutics(TM) and Generx(R) are trademarks of CardiumTherapeutics, Inc.

Tissue Repair(TM), Gene Activated Matrix(TM), GAM(TM), and Excellarate(TM) are trademarks of Tissue Repair Company.

InnerCool Therapies(R), InnerCool(R), RapidBlue(TM) and CoolBlue(TM) are trademarks of InnerCool Therapies, Inc.

Other trademarks are the property of their respective owners.


'/>"/>
SOURCE Cardium Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine news :

1. An international first at the CHUM - Promising treatment in regeneration of the myocardium through the use of stem cells
2. Cardium Reports on Recent Highlights and Financial Results
3. Cardiums InnerCool Therapies Unit Announces Australian Distribution Agreement for CoolBlue and Rapid Blue Systems
4. Cardium Announces InnerCools Endovascular Cooling to be Featured on Science Channels Series Cool Stuff: How It Works
5. Cardium Completes $6.0 Million Financing
6. Cardium Announces Investor Presentation and Corporate Update Webcast
7. Cardium Reports on New York Citys Adoption of Therapeutic Cooling Protocols for Cardiac Arrest Patients
8. Cardium Reports on Exchange Listing With NYSE Alternext US
9. Cardiums InnerCool Announces Launch of New Enhanced Website
10. Cardiums InnerCool Reports on Expanding Use of Therapeutic Hypothermia
11. Cardiums Exchange Listing Compliance Plan Accepted by NYSE Alternext US
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... April 17, 2015 “We have seen healing, ... the past and present,” said Chaplain Shawn Kafader of Friendship ... felt like they had anything to contribute have created beautiful ... overseen a new art therapy program that was launched to ... Masters student from School of the Art Institute in Chicago, ...
(Date:4/17/2015)... April 17, 2015 In Defense of ... following statement: “On Wednesday April 15th, the European Parliament ... a resolution recognizing the Armenian Genocide, “paying tribute, on ... the one-and-a-half million innocent Armenian victims who perished in ... extols the EU for this timely and needed recognition ...
(Date:4/17/2015)... April 17, 2015 Representatives Jim Himes ... and Treatment Act HR 1849 in congress on April ... and treatment for patients with the genetic disease. ... past, would be the first to create a federally ... treatment of hereditary hemorrhagic telangiectasia. This would effectively prevent ...
(Date:4/17/2015)... As a board-certified orthopedic surgeon, Dr. Steven ... platelet-rich plasma (PRP) and stem cell therapy. ... for its world-class care of injury-caused and chronic joint ... in many other physicians offering regenerative medicines. , ... pain management and rehabilitation. Dr. Meier and MOSM can ...
(Date:4/17/2015)... (PRWEB) April 17, 2015 Most dental ... dental restoration units are made overseas by foreign dental ... domestic labs remain unregulated in more than 40 states ... National Association of Dental Laboratories has created ... raise awareness among patients about the consequences that could ...
Breaking Medicine News(10 mins):Health News:Healing At Friendship Village Due To Art Therapy 2Health News:In Defense of Christians Condemns Armenian Genocide 2Health News:In Defense of Christians Condemns Armenian Genocide 3Health News:House Representatives Introduce Bill to Fight Genetic Disease 2Health News:Platelet-Rich Plasma, Stem Cell Therapy Now Offered By Dr. Meier At MOSM in Beverly Hills, California 2Health News:Platelet-Rich Plasma, Stem Cell Therapy Now Offered By Dr. Meier At MOSM in Beverly Hills, California 3Health News:National Association Urges Transparency in Dental Industry 2
... that computerized prescription could be used to avoid medical mistakes, ... to even more errors. ,It is known that adverse ... hospitals each year. One way hospitals are trying to cut ... But according to a new study, use of computerized systems ...
... antihypertensive strategies that use calcium channel blockers and ... with beta-blockers and diuretics. ,Hypertensive patients either ... without the ACE inhibitor perindopril or the beta-blocker ... ,The trial ran for five years, but it ...
... common form of brain cancer might fare better with a ... ,Based on findings of the study it was seen ... glioblastoma receive surgery to remove as much of the cancer ... study compared 573 patients with glioblastomas who were randomized to ...
... say they have now identified a gene variant that ... which in turn could lead to improved understanding of ... to latest research it was seen that specific changes ... associated with an increased incidence of Alzheimer’s. ,In ...
... people it was found that men who drank six cups ... 12 to 18 years, while women who drank that amount ... their study revealed an unequivocal evidence for an inverse and ... other risk factors. However researchers say the reasons for ...
... Switzerland it was seen that the frequency of withholding ... a patient’s life varies greatly among European countries. The ... in diagnostics and treatment to save and sustain life. ... patient’s life, physicians may refrain from using all possible ...
Cached Medicine News:
(Date:4/17/2015)... DUBLIN , Apr. 17, 2015 Research ... announced the addition of the "Medical Device ... to their offering. This report analyzes ... US$ Million by the following Device Categories: Class ... areas also analyzed in the report Include - ...
(Date:4/17/2015)... 17, 2015  Trovagene, Inc., (NASDAQ:  TROV) a ... clinical data presented at the 2015 European Lung ... Cancer Monitoring ℠ (PCM) platform outperformed tissue ... EGFR T790M mutations in metastatic lung cancer ... T790M Mutation in Urinary Circulating Tumor DNA from ...
(Date:4/17/2015)... 2015 Steven Rash , the CEO of ... operating subsidiary American Seed & Oil Company, presented the ... yesterday in New York City.  Mr. Rash,s presentation featured ... Seed & Oil Company has recently announced the ... Seed Foods , the EpiVape , and ...
Breaking Medicine Technology:Medical Device Outsourcing (Radiology, Orthopedic, Neurology, Cardiology, and Others) Market 2015 - Global Strategic Business Report 2Medical Device Outsourcing (Radiology, Orthopedic, Neurology, Cardiology, and Others) Market 2015 - Global Strategic Business Report 3Trovagene's Urinary ctDNA Assay Outperforms Tissue Biopsy in Clinical Study for the Detection of EGFR T790M Mutations in Metastatic Lung Cancer Patients 2Trovagene's Urinary ctDNA Assay Outperforms Tissue Biopsy in Clinical Study for the Detection of EGFR T790M Mutations in Metastatic Lung Cancer Patients 3Trovagene's Urinary ctDNA Assay Outperforms Tissue Biopsy in Clinical Study for the Detection of EGFR T790M Mutations in Metastatic Lung Cancer Patients 4American Seed & Oil Company Benchmarks its Consumer Product Development Strategy Against Proctor & Gamble 2American Seed & Oil Company Benchmarks its Consumer Product Development Strategy Against Proctor & Gamble 3
Total IgE Control...
The K-ASSAY Lp(a) Control Set is intended for use as an assayed quality control material for monitoring the performance of Lp(a) immunoturbidimetric assays....
... The K-ASSAY ASO / ... is intended to be used ... of known concentration for monitoring ... O (ASO), Rheumatoid Factor (RF), ...
Eppendorf expands its line of benchtop microcentrifuges with the 5418. This easy-to-use microcentrifuge features a certified aerosol-tight rotor and a unique, contoured rotor bowl design to reduce no...
Medicine Products: